After a 2019 guideline, specialists prescribed more SGLT2 inhibitors to targeted patients
A Medicare study published Oct. 1, 2026, in JAMA Network Open found that after the 2019 diabetes guideline update, SGLT2 inhibitor fills rose 11.4 percentage points in the patients it targeted, more…